榮昌生物(09995.HK)完成配售1900萬股H股 淨籌約8億港元用於投資核心產品泰它西普等
格隆匯5月29日丨榮昌生物(09995.HK)宣佈,配售協議所載配售的全部先決條件均已達成(包括取得上市委員會就配售股份上市及買賣的批准),並已於2025年5月29日完成配售。
於2025年5月29日,公司成功按配售價每股配售股份42.44港元向不少於六名承配人配發及發行合共1900萬股新H股,佔配售股份配發及發行後經擴大已發行H股總數的約9.11%及已發行股份總數的約3.37%。
假設所有配售股份已獲配售,配售所得款項總額預計為8.0636億港元,而配售所得款項淨額預計約為7.96億港元。配售已悉數進行。集團擬將配售所得款項淨額的90%用於投資核心產品泰它西普(RC18)的研發及其核心適應症拓展(如重症肌無力、膜性腎病),預期將於2027年12月31日前悉數使用,並擬將配售所得款項淨額的10%用於一般企業用途,預期將於2025年12月31日前悉數使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.